Two-year oral IL-23 data, GLP-1 biomarker findings, and a nonsurgical option for superficial basal cell carcinoma headline the sessions covered in Las Vegas.
Poll|Articles|January 29, 2024
POLL: Are You Attending IMCAS World Congress 2024?
Author(s)Kaitlyn Bader, Senior Editor
Let us know if you plan to attend IMCAS World Congress 2024.
Advertisement
Are you attending IMCAS World Congress 2024?
Dermatology Times is headed to France to attend the 25th annual IMCAS World Congress in Paris. IMCAS is one of the largest scientific aesthetic congresses worldwide that brings together 15,000 attendees, 980 speakers, 350 exhibitors, and has 136 countries represented.
During the 3-day congress, expert clinicians will present data and new techniques on topics such as exosomes, navigating AI, hair restoration, skin aging, and more.
Stay tuned for more content from Dermatology Times, including an exclusive pigmentary disorders panel chaired by Hema Sundaramm, MD and hosted by La Roche-Posay.
Email us at
Advertisement
Related to this article
A retrospective claims analysis of 2897 matched pairs found hazard ratios of 0.48 to 0.67 for new atopic disease with dupilumab vs systemic corticosteroids in children.
Prospective data suggest DecisionDx-Melanoma may help refine SLNB decisions and identify recurrence risk beyond conventional staging.
Falk G. Bechara, MD, discusses long-term tunnel control, structural damage, and the evolving role of biologics and surgery in HS care.
In a survey of 301 employed adults, overall work impairment attributable to CHE was 31.8%, and quality of life worsened in step with self-reported disease severity.
Christophe Piketty discusses 3-year ARCADIA data demonstrating sustained efficacy and long-term safety of nemolizumab in atopic dermatitis.
Two claims analyses of hidradenitis suppurativa showed similar symptom prevalence in males and females and lower dermatologist access among rural patients than urban patients.
Day 3 of Fall Clinical 2026 featured roflumilast data in genital psoriasis, long-term JAK inhibitor safety in atopic dermatitis, and expert insights on setting expectations in HS, treating advanced cSCC, and screening aesthetic patients.
Advertisement
Advertisement
Trending on Dermatology Times
1
AAD, HS Foundation Issue First Joint Hidradenitis Suppurativa Guidelines
2
Dupilumab Associated With Lower Atopic March Risk in Pediatric Atopic Dermatitis
3
Individualizing Systemic Therapy for Alopecia Areata Across Patient Cases
4
Skin Longevity Needs Evidence, Not Hype
5